Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects

BACKGROUND: Data on the safety and efficacy of coronavirus disease 2019 (COVID-19) vaccination in people with a range of primary immunodeficiencies (PIDs) are lacking because these patients were excluded from COVID-19 vaccine trials. This information may help in clinical management of this vulnerabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Michele N., Murugesan, Kanagavel, Banaei, Niaz, Pinsky, Benjamin A., Tang, Monica, Hoyte, Elisabeth, Lewis, David B., Gernez, Yael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690218/
https://www.ncbi.nlm.nih.gov/pubmed/34952033
http://dx.doi.org/10.1016/j.jaci.2021.11.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690218/
https://www.ncbi.nlm.nih.gov/pubmed/34952033
http://dx.doi.org/10.1016/j.jaci.2021.11.022

Ejemplares similares